With an Impact Factor of 5.016 there has never been a better time to submit your next paper to us.
Submit your next paper and find out what publishing benefits we offer...
Opt2Pay The Biochemical Journal is fully compliant with funding body mandates including NIH. Read our FAQs
Peter Shepherd talks about the Biochemical Journal reviewing process, the Journal's painless publishing strategy, metrics and advances in science publishing.

In this BJ Signal Readers' Choice article, Daniel Kirchhofer and Domagoj Vucic discuss a recently published article by Guy Salvesen and colleagues, who have provided novel insights into the activation mechanism and the substrate specificity of the human paracaspase MALT1, opening up possibilities for novel therapeutic approaches that target this crucial regulator of lymphoma survival and proliferation.

In this BJ ChemBio paper, Marek Nagiec and colleagues report on the discovery and characterization of PF-543, a novel cell-permeant inhibitor of SphK1 (sphingosine kinase-1) which has a more-than-100-fold greater selectivity for SphK1 over the SphK2 isoform. Read the commentary on this paper written by Kevin Lynch.

In this BJ Cell paper, which is freely available to all users, James Bear and colleagues have identified a second actin-binding site in the unique region of Coronin 1C that confers co-operative binding to F-actin, and discuss the implications of their work in relation to how coronins orchestrate cytoskeletal dynamics.